Cristiano P
Institute of Internal Medicine, 1st Medical School, Naples University, Italy.
Drugs Exp Clin Res. 1989;15(1):17-20.
A clinical trial was carried out to evaluate the effectiveness of treatment with imipenem/cilastatin in life-threatening infections in high-risk patients. Thirty hospitalized patients (22 men and 8 women), aged 28 to 78 years, with impaired host defences and severe infections were treated with imipenem/cilastatin at a dosage ranging between 1 and 3 g daily i.v. at 8 or 12 h intervals. The average length of therapy was 8.61 +/- 3.14 days. The isolated organisms were as follows: Escherichia coli [7], Pseudomonas aeruginosa [9], Staphylococcus aureus [5], Streptococcus faecalis [3], Strep. viridans [1], Proteus mirabilis [1], P. vulgaris [2], Klebsiella pneumoniae [2], Citrobacter freundii [2], Bacteroides fragilis [2]. In only one patient the aetiological agent remained unknown and in five patients (16.67%) a mixed infection was observed. Twenty-four patients (80%) were completely cured of infection and 29 isolated organisms (82.86%) were eradicated. No important side-effects were observed.
进行了一项临床试验，以评估亚胺培南/西司他丁治疗高危患者危及生命感染的有效性。30名住院患者（22名男性和8名女性），年龄在28至78岁之间，宿主防御功能受损且患有严重感染，接受了亚胺培南/西司他丁治疗，静脉注射剂量为每日1至3克，每8或12小时一次。平均治疗时长为8.61±3.14天。分离出的病原体如下：大肠杆菌[7株]、铜绿假单胞菌[9株]、金黄色葡萄球菌[5株]、粪肠球菌[3株]、草绿色链球菌[1株]、奇异变形杆菌[1株]、普通变形杆菌[2株]、肺炎克雷伯菌[2株]、弗氏柠檬酸杆菌[2株]、脆弱拟杆菌[2株]。仅1例患者的病原体仍不明，5例患者（16.67%）观察到混合感染。24例患者（80%）感染完全治愈，29株分离出的病原体（82.86%）被根除。未观察到严重副作用。
